Neo- oder adjuvante Chemotherapie beim Harnblasenkarzinom?

Translated title of the contribution: Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?

M. C. Hupe, M. W. Kramer, M. A. Kuczyk, A. S. Merseburger*

*Corresponding author for this work
1 Citation (Scopus)


Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. In metastastic patients, the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). For second-line treatment, vinflunine is the only approved therapeutic agent.

Translated title of the contributionNeoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?
Original languageGerman
JournalAktuelle Urologie
Issue number3
Pages (from-to)242-247
Number of pages6
Publication statusPublished - 15.05.2015


Dive into the research topics of 'Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?'. Together they form a unique fingerprint.

Cite this